Pancreas Cell Therapy
Type 1 Diabetes
Proof of ConceptActive
Key Facts
About LyGenesis
LyGenesis is developing a revolutionary cell therapy platform that uses lymph nodes as in vivo bioreactors to grow functional ectopic organs, potentially solving the critical supply-demand imbalance in organ transplantation. Its most advanced program is a Phase 2a trial for end-stage liver disease, with proof-of-concept data also established for thymus (aging), kidney, and pancreas (Type 1 diabetes) indications. The company's technology, founded on pioneering research by Dr. Eric Lagasse, could dramatically reduce the cost, complexity, and risk of treating organ failure, representing a paradigm shift in regenerative medicine.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |